帕博利珠单抗对比安慰剂辅助治疗已切除高危II期黑色素瘤:随机3期KEYNOTE-716研究健康相关生活质量结果
KEYNOTE-716研究显示,在已切除IIB和IIC期黑色素瘤中,帕博利珠单抗辅助治疗较安慰剂显著改善无复发生存期。本报告分析健康相关生活质量,共969例患者纳入分析(帕博利珠单抗483例,安慰剂486例),第48周时两种量表依从性均≥80%。两组EORTC QLQ-C30总体健康状况/生活质量、躯体功能、角色功能及EQ-5D-5L视觉模拟量表评分从基线至第48周保持稳定,未见有临床意义的下降,两组间评分无显著差异,且至第96周仍保持稳定。
要点
- 帕博利珠单抗辅助治疗组与安慰剂组EORTC QLQ-C30总体健康状况/生活质量、躯体功能、角色功能及EQ-5D-5L视觉模拟量表评分从基线至第48周稳定,未见有临床意义的下降。
- 两组上述评分在第48周无显著差异,且至第96周仍保持稳定。
- 第48周时两种量表的依从性均≥80%。
核心结论
- 帕博利珠单抗辅助治疗期间健康相关生活质量保持稳定,未见有临床意义的下降,且两组间从基线变化相似。
- 结合此前报告的无复发生存期改善和可控的安全性,这些结果支持帕博利珠单抗用于高危II期黑色素瘤的辅助治疗。
研究设计与样本
- 随机3期KEYNOTE-716研究,患者按1:1随机分配至帕博利珠单抗200 mg(2 mg/kg,≥12至<18岁患者)每3周一次或安慰剂,最多17个周期,或直至疾病复发、不可接受毒性或退出。
- 健康相关生活质量分析人群为接受至少1剂治疗并完成至少1次评估的患者,共969例(帕博利珠单抗组483例,安慰剂组486例)。
- 主要分析在第48周进行,以确保足够的完成率和依从性。
主要发现
- 第48周时两种量表的依从性均≥80%。
- 两组EORTC QLQ-C30总体健康状况/生活质量、躯体功能、角色功能及EQ-5D-5L视觉模拟量表评分从基线至第48周保持稳定,未见有临床意义的下降。
- 帕博利珠单抗组与安慰剂组上述评分无显著差异。
- 两组EORTC QLQ-C30总体健康状况/生活质量、躯体功能、角色功能及EQ-5D-5L视觉模拟量表评分至第96周仍保持稳定。
临床怎么用
- 作者认为,结合此前报告的无复发生存期改善和可控的安全性,这些结果支持帕博利珠单抗用于高危II期黑色素瘤的辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. METHODS: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients ≥12 to <18 years) Q3W or placebo for ≤17 cycles or until disease recurrence, unacceptable toxicity, or withdrawal. Change from baseline in EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) was a prespecified exploratory end point. Change in EORTC QLQ-C30 functioning, symptom, and single-item scales, and EQ-5D-5L visual analog scale (VAS) were also summarized. Primary analyses were performed at week 48 to ensure adequate completion/compliance. The HRQoL population comprised patients who received ≥1 dose of treatment and completed ≥1 assessment. RESULTS: The HRQoL population included 969 patients (pembrolizumab, n = 483; placebo, n = 486). Compliance at week 48 was ≥80% for both instruments. EORTC QLQ-C30 GHS/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores were stable from baseline to week 48 in both arms, with no clinically meaningful decline observed. Scores did not differ significantly between pembrolizumab and placebo. EORTC QLQ-C30 GHS/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores remained stable through week 96 in both arms. CONCLUSIONS: HRQoL was stable with adjuvant pembrolizumab, with no clinically meaningful decline observed. Change from baseline in HRQoL was similar between arms. These results, in conjunction with the improved RFS and manageable safety previously reported, support the use of adjuvant pembrolizumab for high-risk stage II melanoma.
引用
- Khattak MA, Luke JJ, Long GV, et al. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer. 2022. PMID: 36202690. doi:10.1016/j.ejca.2022.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。